Agoracom Blog Home

Archive for the ‘Empower Clinics Inc.’ Category

Empower Clinics $CBDT.ca Enters Canadian Market with Proposed Acquisition That Includes 6 Clinics and Incentives to Open Additional 30 Clinics and Announces Private Placement of Up to $1.1 Million $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 5:14 PM on Wednesday, October 21st, 2020
  • Announced it has entered into a non-binding term sheet to acquire the businesses of Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc dba Atkinson, and Momentum Health Inc. collectively (“Momentum Health“).
  • Momentum Health operates a network of medical clinics with a comprehensive team of physicians and therapists who apply a holistic and hands on approach working with patients to unlock potential well-being.
  • 6 clinics in greater Toronto area with plans to expand
  • Closing will be conditional upon, amongst other customary items listed below, Empower completing a debt or equity financing to raise minimum gross proceeds of $750,000 CAD
  • To this end, the Company has entered into an agreement with Mackie Research Capital Corporation in connection with a best efforts, private placement for gross proceeds of up to $1,100,000, the details of which are outlined below
  • The private placement is scheduled to close on or about the week of November 2, 2020.

Acquisition Expands Company’s North American Footprint And Strengthens Vertical Integration From Patients To Laboratory

VANCOUVER, BC / October 21, 2020 / Empower Clinics (CSE:CBDT)(OTC PINK:EPWCF)(FRA:8EC) (the “Company” or “Empower“), a vertically integrated health and wellness company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and a world-class medical diagnostics laboratory, is pleased to announce it has entered into a non-binding term sheet to acquire the businesses of Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc dba Atkinson, and Momentum Health Inc. collectively (“Momentum Health“).

Closing will be conditional upon, amongst other customary items listed below, Empower completing a debt or equity financing to raise minimum gross proceeds of $750,000 CAD. To this end, the Company has entered into an agreement with Mackie Research Capital Corporation in connection with a best efforts, private placement for gross proceeds of up to $1,100,000, the details of which are outlined below. The private placement is scheduled to close on or about the week of November 2, 2020.

Closing of the acquisition is expected to occur on or about November 10, 2020.

6 CLINICS IN GREATER TORONTO AREA WITH PLANS TO EXPAND MODEL ACROSS CANADA

Momentum Health operates a network of medical clinics with a comprehensive team of physicians and therapists who apply a holistic and hands on approach working with patients to unlock potential well-being. Key services include Physiotherapy, Chiropractic, Massage Therapy, Traditional Chinese Medicine, Athletic Therapy and others.

The proposed acquisition will include the acquisition of two standalone wellness clinics and four new co-located clinics in the Greater Toronto area of Ontario, Canada. Moreover, the proposed acquisition includes incentives for the two Co-Founders of Momentum Health to open an additional 30 clinics across Canada.

Steven McAuley, Chairman and CEO of Empower Clinics stated, “The acquisition of Momentum Health is expected to advance the direction and growth prospects for Empower overall,” said Steven McAuley, Empowers Chairman & CEO. “As we continue to position Empower as an integrated healthcare company, bringing alternative care together with primary care facilities enables us to deploy a better healthcare model, based on progressive technology and in-person care. Having Dr. Rabinowitz and Dr. Tsimerman join me in leadership to rapidly expand Empowers clinic footprint across Canada is another important step toward our growth objectives.”

Momentum Health Co-Founder Dr. Rabinowitz commented “Our core values of professionalism, corporate responsibility and community health fall directly in line with Empower. We are extremely excited to collaborate with this tremendous organization to provide reliable and trusted healthcare for communities across Canada.”

Momentum Health Co-Founder Dr. Tsimerman commented “Momentum Health has always stood on the foundations of providing an unparalleled patient experience and bridging the gap between the conventional medical system and paramedical services.”

PROPOSED TERMS OF ACQUISITION

Under the proposed terms, the Company will pay $275,000 CAD cash at closing and a $75,000 CAD performance holdback, for an aggregate cash payment of $350,000 CAD. In addition, at closing, Empower will issue Dr. Jordan Rabinowitz and Dr. Aviv Tsimerman common shares in the capital of Empower (“Shares“) having an aggregate value of $250,000 CAD and, subject to the satisfaction of defined performance metrics, additional Shares having an aggregate value of $250,000 CAD, which will vest in quarterly installments over 24 months following the closing. All Share consideration is expected to be based on a deemed price per Share equal to the 10-day volume weighted average closing price per Share on the Canadian Securities Exchange (the “CSE“) for the period ending on the last business day prior to the closing.

PERFORMANCE INCENTIVES TO OPEN 30 ADDITIONAL LOCATIONS

The proposed acquisition also includes long-term performance incentives that upon achieving the opening of:

Ten (10) new clinic locations (“Milestone One”) the issuance to the Vendors subject to terms and conditions as set out in the Stock Option Plan, an irrevocable option (the “Share Option“) to purchase at any time or from time to time on or before the Expiration Date, 1,250,000 Shares of the Corporation.

Twenty (20) new clinic locations (“Milestone Two”) the issuance to the Vendors subject to terms and conditions as set out in the Stock Option Plan, an irrevocable Share Option to purchase at any time or from time to time on or before the Expiration Date, 1,250,000 Shares of the Corporation.

Thirty (30) new clinic locations (“Milestone Three”) the issuance to the Vendors subject to terms and conditions as set out in the Stock Option Plan, an irrevocable Share Option to purchase at any time or from time to time on or before the Expiration Date, 1,250,000 Shares of the Corporation.

All issuances will be at a deemed price per Share equal to the 10-day volume weighted average closing price per Share on the CSE for the period ending on the last business day prior to the achievement of Milestone One, Two or Three.

ADDITIONAL DETAILS

The proposed consideration assumes a debt free transaction and will be adjusted accordingly for any level of debt assumed by the Company, directly or indirectly. The transaction is expected to be structured on a tax efficient basis, and otherwise in accordance with the requirements of requisite securities laws and the policies of the CSE.

Empower has agreed to enter into employment agreements with Dr. Rabinowitz and Dr. Tsimerman, to lead the proposed Canadian clinic expansion strategy.

Completion of the transaction includes Momentum Health interests in certain affiliates and will be subject to various conditions, including entry into a definitive agreement, completion of due diligence, and receipt of all required shareholder, manager, third party and regulatory approvals, including approval of the CSE.

PRIVATE PLACEMENT

The Company is also pleased to announce that it has entered into an agreement with Mackie Research Capital Corporation, as sole agent and sole bookrunner (the “Agent“), in connection with a best efforts, private placement of units of the Company (the “Units“) at a price of $0.05 per Unit (the “Offering Price“) for gross proceeds of up to $1,100,000 (the “Offering“).

Each Unit will be comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“). Each Warrant shall be exercisable to acquire one Common Share (a “Warrant Share“) at a price of $0.12 per Warrant Share for a period of 24 months from the closing of the Offering.

The Agent will have an option (the “Agent’s Option“) to offer for sale up to an additional 15% of the number of Units sold in the Offering at the Offering Price, which Agent’s Option is exercisable, in whole or in part, at any time up to 48 hours prior to the closing of the Offering.

The Company intends to use the proceeds raised under the Offering to support the development of clinics through clinic acquisitions, lab testing services, sales and marketing, for general working capital purposes.

The securities to be issued under the Offering will be offered by way of private placement in each of the provinces of Canada, and such other jurisdictions as may be determined by the Company, in each case, pursuant to applicable exemptions from the prospectus requirements under applicable securities laws.

The Offering is scheduled to close on or about the week of November 2, 2020, or such date as agreed upon between the Company and Agent (the “Closing“) and Closing of the Offering may occur in multiple tranches, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Canadian Securities Exchange. The Units to be issued under the Offering will have a hold period of four months and one day from Closing.

In connection with the Offering, the Agent will receive an aggregate cash fee equal to 8.0% of the gross proceeds from the Offering, including in respect of any exercise of the Agent’s Option. In addition, the Company will grant the Agent, on date of Closing, non-transferable compensation options (the “Compensation Options“) equal to 8.0% of the total number of Units sold under the Offering (including in respect of any exercise of the Agent’s Option). Each Compensation Option will entitle the holder thereof to purchase one Unit at an exercise price equal to the Offering Price for a period of 24 months following the Closing.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Momentum Health acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

VIDEO – Loop Insights and Empower Clinics Team Up To Create First Ever “Travel Bubble” Solution For Global Travel Industry

Posted by AGORACOM-JC at 11:30 AM on Tuesday, October 20th, 2020
https://miro.medium.com/max/3150/1*f9msDHyceA_TbRM30jQhsw.png

Welcome to beyond the press release of production of AGORACOM which we speak the small cap executives right after they put up for news today we’ve got not 1 but 2 companies on Empower Clinics trade on the CSE and the stock symbol CBDT and the U. S. under EPWCF we got Steve McAuley of Empower Clinics for those who knew the story that’s gonna be a lot you can get a lot of market attention a vertically integrated health and wellness company their server database but 165,000 patients through clinics in the southwest US plus a telemedicine platform and a world class medical diagnostics lab more than just lip service they’ve out they’ve shown continued growth on patient revenue income side for Q. 4 Q. 1 Q. 2 the other company with us Loop Insights trades on the stock symbol M. T. R. X. and for friends the U. S RACMF a provider of contactless solutions and artificial intelligence to drive real time insights enhance customer engagement automated contact tracing to the brick and mortar space again more just lip service there they’ve had tremendous success also just recently announced a great agreement would tell us we’re going to resell their their products all over Canada Vegas bubble were gonna be providing venue tracing a contact based solutions as well as are a number of other ones they rob believe what you guys have been able to do in the last 30 days. The headline we’re talk about today these companies have combined venue tracing with Covid-19 expertise to create the first ever travel bubble solution for the global travel industry that’s set to lose 3B, gentleman welcome to the show. George thanks for having us.  Guys this is a great press release in fact it’s almost unimaginable how big this is the 2 Canadian small cap covers gonna be able to tackle it before getting some the details you guys are 2 parts of this troubled solution so let’s walk through it briefly so people understand how this practically applies to the let’s start with the loop because you’re the front end facing part of the solution rob so maybe you can walk through that and they will move on to start a Steve on the Empower side with the Covid 19 testing part. Sure and and I’ll use the airline San Juan to Sam I guess with the cruise ships but. The challenge right now is our government needs to wake up I mean Dam they’re shutting down economies one of the only countries I’m not blaming Canada. But you know then to have no plan in place to eliminate the 14 day quarantine is absolutely absurd you know now there’s articles coming out that the Canadian government’s looking to buy a position. So I’m not really sure what agenda our government’s looking out for but it’s most definitely not about small business and that’s a fact so providing their lines the cruise ship the hospitality industry the ability to re open now is what Empower so in our case we have an end to end solution for tracing for payments for contactless engagement as we’ve talked about before when you add now the power of what Empower in the lab testing capabilities there is no need for 14 day quarantine. The minute that that you know person comes off the plane there’s ability now to have testing set out that complete security around all of the results and I have anonymity and what I mean by that is right now all of these news articles and I keep reading and on the on the radio on global too in other news at 90. It’s just a cry and it’s Hey we’ve had exposures come out by us and you know everyone just gets more anxious there’s no need for that with our platform the audience is 100 percent segmented and it’s only notified directly to your phone whether it’s an email a voice call whatever it may be there’s no need for this generalized red alert oh my goodness. Steve your side is the testing side which is easier obviously equally critical this because with loops are I’ve got on my phone it’s a wallet pass I can get on the plane I could be identified I can be alerted. Where does Empower fit in all this. Yeah this is this is a great partnership for us I mean we have been spending some time working with rob and his team going through the platform and understanding and I could tell you on this is state of the art technology on its effective but most importantly it’s simple and it’s it’s easy to use that’s functional so when we think about what our strengths are so think of the supply chain of testing so there’s the front and specimen collection however that might take place in and you’ve seen without prior releases you we are now you’re deep in our 4 stage national rollout of our testing platform but then the others great asset that we have in our books now is trying medical laboratory it has the capability of not only providing rapid tests are to be deployed at point of collection but also to do the back and PCR testing of which we can process for thousands of specimens per day right now that’s our current capacity so given the capacity that we have the scientific expertise having the ability to run the specimen collection at points all of us at that point all with the patients or the consumer might be and then combining with large testing capability we think putting the 2 yes assets together is it is a tremendous solution to help open up the economy and Steve you say simple and easy but that’s only because you made it simple and easy it’s not something very many companies can do don’t don’t sell yourself short that’s for sure. Rob I’m gonna go I’m gonna take a excerpt from the press release here because this is not just too small cap companies getting together and saying Hey let’s slop or solution together and see we can come up with a quote the company advises discussions are already underway with major airlines cruise ship operators and hotel rob can you give us a little bit of insight into what those conversations are looking like what the urgency is like and the acceptance of of this travel bubble solution. Sure it says its dynamic because there’s just so many so many challenges right now George we got boats that are traveling around the ocean empty you’ve got airlines that are struggling to gain confidence you’ve got people that are looking to go you know see family I mean I’ve I’ve got a buddy his you know down in the US is on his deathbed love not not nothing more to go see him but. 14 day quarantine. Like it’s it’s it’s asinine so the challenges are all everybody and it’s not just these these industries here the mom and pop grocery store and convenience store on the corner everyone has to remain remain open. Where where today in an article here with Steve is. To put a plan in place to present. Container again to the government to show them exactly now how we can reopen the private sector because right now putting your head in the sand sending everybody home for 2 weeks again in Toronto is doing anything that there’s still no good at all sell resulting in factors be there either protest mystery now people saying you were just not going to do it it is it’s nonsense and you know the next couple weeks here I think you’re absolutely imperative from government and to see someone stuff up Alberta is is starting to be some of that article when their health minister I mean they’re even more rougher shape so it’s not going anywhere putting that in the sense not solving anything so we’re providing them a turn key solution that starts that can be replicated over and over and over. So it’s not just airlines and cruise ship operators talk to but also governments that these discussions about it and if you don’t mind can you give us a sense for what those conversational like are they well advanced on the right the very beginning and what is what’s the what’s the excitement on the other side that you you guys may have a solution. Well I mean to be honest with you and of course I can’t say too much but that were way down the path we know that’s not a surprise to anyone you know they’re there the belief that the federal tracing apps gonna solve all the problems we know that’s not reality we all knew was gonna take a multitude of solutions and the private sector is going to play a big part of that I mean this this look back in time for decades and decades this is not a surprise to anyone so we’re way way down the path of the escalation of called it in phase 2 phase 3 depending upon how you’re talking to is here upon us and inevitable to grow look at the global numbers in the press release how many countries are shut down it’s not just here in Canada this is a global issue. On that note Steve there is also part of the press which word you guys make a joint statement says  empower believe the travel bubble combination of frequent testing robots in national trade platform provides the antenna production nested to spark a strong global economic recovery I mean you know that’s all I’m gonna play devil’s advocate say that almost seems too good to be true but the fact of matter is someone has to save the day and someone has to save the world at the end of the day and looks like it it may be you guys can you speak more to that as to you know whether that’s done almost intimidate you as the as the size of the problem or your confidence level that yeah we can actually solve this. It did the size of the problem is has incredible magnitude it doesn’t necessarily intimidate us all we know we can’t solve every country’s problems are but we know that we can definitely get to private sector public sector and bring this solution to the table as as rob and I were discussing you know how to put an implementation plan in place yeah we quickly realized that we’re both having independent conversations with small medium and large entities and if we could cross reference those opportunities and bring in more viable young cohesive solution together because you need contact tracing and testing you know one without the other isn’t a complete solution so again it was really relatively obvious for us that if we can find a way to really collaborate and work together we got a fighting chance to make a difference and to make an impact we think we can make a scalable impact on to this right now it’s about getting awareness out but I can tell you that I go right from this call into a large group that owns elder care facilities in all the southwest United States there are thousands of patients and their families that are impacted just by this one conversation that I’m having rocks having the same conversations with large organizations like U. N. C. to weigh in and the tech bubble is coming up and will be on the bubble is coming up in Las Vegas we’ve already been in discussions with cruise lines we know that rob’s been in discussions with cruise lines so as your rob used the word dynamic a little bit earlier that’s what it’s like for us right now it’s it’s it’s kind of wild and dynamic and crazy but we’ve got a solution that we believe is extremely viable and is going to make an impact to getting this economy back up and running Hey rob is a tiny perfect here because if you guys try to you know do. This 6 months ago you would have had tell us third party validation the Vegas bubble for the NC double a the university of Houston Steve would have had the time to show Q. 4 Q. one Q. 2 growth the acquisition of this massive lab in Dallas Texas right in the heart of the medical world there so when you’re having these conversations how much does your success with some of these names come into play because I got assume that’s very important  just can’t come along so we got a solution even if we have it. This that faith in conference might not be there but you guys have it because of you’ve got third party validation. What is time is everything in business and life and it’s much like our ticker symbol people always ask me what is matrix as evidence the watch the movie everything always happens for a reason and you know let’s say 7 not that I’m taking credit for you know cold it but its foresight around digital transformation and you know what without a transformative solution or future proof roadmap we’re gonna be hung out here high and dry for decades to come the financial burden that this is put on by the Canadian population areas it’s it’s still it’s sickening and then out there’s no need to go hire more people throw more money at it this is what artificial intelligence and automation is about. Is about machine learning it’s about managing these processes like we build here was Steve. It it’s it’s it’s a little frustrating they can tell their yeah I’d like to tell you are we all are on I’m glad yeah I think it right it is and you know right now is the perfect timing and like I said when. When when we get in these conversations we deliver and at the end of the day you know there’s a a global problem anyone just punching Covid-19 revolt protest whatever maybe I mean you see videos of you know cities burning burned down again I mean it’s it’s it’s rather alarming at its time here that groups like Empower and Lop come together and deliver something that’s. Black and white in front of them here we go Steve is it fair to say that in phase one. We’ll put their faith in government to do the right things and help us get through all this but now in phase 2 are you hearing from you know you are you said useful to cruise ship operates for example and many other major film studios I mean you you’re you’re you you’ve already announced testing for major film studio we already know that is it safe to say that enterprise is much more willing now in fact almost demanding that you guys come forth with the solution because they’ve lost the faith in government. Well I mean I think to keep in mind here the markets you know my current law on major markets are in the US and the US are doesn’t have a cohesive federal strategy to address these issues that we’re talking about right now even at the state level state by state their success or failures very dramatically but there is one consistency in the United States in all states the numbers are out of control again and they’re not getting worse they’re not getting better getting much worse for sure there is our first region there is dissent I’m at all levels and the other thing is happening now in the U. S. this is becoming a legal matter you know we see our society the U. S. as more litigious than perhaps we see back home here to Canada all but we’re we’re seeing and we’re hearing not and to go but we have have not see this going on is that employers are getting sued by employees if that employer is not demonstrating that they’re doing all they can to provide protect or provide health and safety not only for employees but for customers and vendors so you’ve got industries now that are all putting regulation and so if you take film and television you’ve got the screen actor’s guild who are dictating policy if you look at the cruise ship industry the our cruise line international H. R. association are established policies for cruise lines going forward which say all crew staff and passengers must produce a negative coping 19 task 5 days before boarding or they will not be able to board and indeed a very comprehensive contact tracing solution just to pull it all together make it work so is becoming regulated now whether. Federal government’s comment or state governments come in is almost irrelevant at NY times the big industries are now legislating themselves to bring these solutions to market. Hey Rob any decision like this still comes down ROI no matter what money still matters at the end of the day we know the bad though the losses are massive you gave in to you do you get anything stop the other day off on a call about just how much the Ontario or the Canadian government was losing from foreign students not being able to be here talk a little bit to that if you don’t mind and then does that mean does that give you guys pricing power down today because of the losses are so massive known to be bickering over cost they just want a solution to get back to business. Well most definitely I mean no matter what angle you look at it whether it’s from a federal government standpoint. The impact by not having students foreign students attending school in Canada this year will surpass 1B so just think about not just that’s just foreign students. Looking to still reside in Canada to go to university. The numbers are absolutely staggering. Sell side you know I said to you Hey George I can make your headache go away instantly across on $1000000 and look at the numbers you’ve got last. I mean. You know what is some of what is the what is the value that’s what someone’s willing to pay. And right now we’re we’re in a very strong position. And you know it’s the same side of it my my call before this one was one of the major universities in in the south we’re at 50 percent capacity for the ball season coming up. We have very limited revenue now because of it they’re all not just looking for today George in the US where we’re seeing these large enterprise organizations are looking for 2021-2022. 3 year roadmap because they understand this is not going anywhere just like 911 changed the way security and travel covid pandemic right now is forcing digital ID digital wallets and the complete end to end solution so you’re gonna see testing. I guarantee you you mark my words you will see testing in every major airport in our country in the next 6 months to one year. Do you think you guys play a major role in that Steve and rob do you guys think that you know if you’re able if you got this travel bubble that did you guys be a big part of that well I think part of it and once again I think that that’s the reason easy answer yes we’re going to be a part of this for sure you know the the the volume and scale this is substantial and to the extent that we can you know from a business perspective in our partnership I gain some of that market share then I think people are going to quickly realized that we have that capability we have the operational skill set we have the sciences and the diagnostic testing capability and we have an elegance A. I. driven solution for contact tracing so I definitely think that we can play a role in that part of it but as we’ve been discussing here there are so many large assets not for us to to talk about you know we together you know we are already you know independently talking to your division one universities and colleges in the states and their athletic programs you know some of these big division one colleges you know they have their generate in excess of $1B U. S. on their programs per year so that is a significant revenue that has been lost and they’re not going to regain it that’s read on walks so now is as we’re rob says. How are they going to plan to resolve this business problem that they have in years ahead there to figure out how to regain it in a safe and healthy manner again for all of the people who are in their system your players and coaches and staff but also the fans and without the fans attending then they really can’t generate the revenue streams that they they normally expect. Jets jets I know you both have I mean you’ve done it everyone a great service here by jumping on the middle day you both have hard stops in 2 minutes which is great because you speak to potential customers so rob maybe I’ll ask you is it is it safe to assume that you know you can expect to see some kind of uptake commercialization coming out of this. In the near future or is it still going to be up a long sales cycle in order to get this done. No I I think it’s it’s it’s very near I mean that. The the the thing that we’ve built here George this can be replicated in every city across the world I mean it’s it’s where our data platform that can connect to any lab testing group globally so doesn’t matter which government doesn’t matter it’s private sector independent whatever maybe and so now this is something like this said here that we are we see great opportunity and we’re going after. There’s so much more we could talk about we’re pretty sure the fact the took out your 20 minutes of your time you know the day congratulations.  Pretty soon their future goes sounds like you’ve already got irons in the fire and not your some shareholder point of view but from a system point of view thanks to you guys have done so far and if you can really you know make this happen then you’re gonna be helping out everybody not just financial mental health stress anxiety all that so good luck to you guys and thanks for joining us right thank you George .  you’ve been watching Steve McAauley of  Empower clinics trades on the CSE and the stock symbol CBDT and for a friends of the US under EPWCF. likewise you been watching Rob Anson of Loop Insights trades of TSX venture exchange of the stock symbol MTRX go watch the matrix if you haven’t you can answer the question and for friends the U. S. RACMF thanks for joining us everyone have a great day see you next time.

VIDEO – Loop Insights $MTRX.ca and Empower Clinics $CBDT.ca Team Up To Create First Ever “Travel Bubble” Solution For Global Travel Industry $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 5:06 PM on Monday, October 19th, 2020
https://miro.medium.com/max/3150/1*f9msDHyceA_TbRM30jQhsw.png

The COVID-19 Pandemic has wreaked havoc on the global economy but perhaps no industry has suffered worse than the travel industry which could suffer an unfathomable loss of $US 3.3 TRILLION (Not A Typo) if it can’t find a practical solution to replace the shut down and / or quarantine measures mandated around the world.  Specifically, as of today, travel restrictions by country are as follows: 

  • 58 countries are completely closed
  • 124 countries are partially open with MANDATORY quarantine upon arrival

Unlike the restaurant business which can mitigate losses through alternative models such as take-out, delivery and outdoor patios, the travel industry has no mitigation solutions.  Countries are either shut down or implementing such strict quarantine requirements that they might as well be shut down.  The only solution is a complete solution that combines venue tracing, contact tracing and rapid testing to give government, airlines and cruise ships the comfort they need to know that travellers are not spreading COVID-19 to each other, or to other countries. 

Loop Insights CEO, Rob Anson confirmed this when he said:

“We have heard from stakeholders in the entertainment, travel, and hospitality industries that have stressed the importance of an end-to-end integrated solution capable of protecting employees and customers to facilitate a safe economic recovery.”

ENTER THE “TRAVEL BUBBLE”

Earlier today, Empower Clinics (CBDT:CSE) and Loop Insights (MTRX:TSXV) announced they have combined forces to provide an end-to-end COVID-19 mitigation solution complete with venue tracing, real-time automated guest exposure notifications and frequent testing with rapid results in 15 minutes.  More than just lip service, each company brings a strong recent track record of success in their respective parts of the bubble as follows:

LOOP INSIGHTS

As the front facing part of the Travel Bubble solution, Loop Insights is a powerful Artificial Intelligence company whose industry leading venue tracing has gained significant traction towards reopening the tourism, hospitality and entertainment industries in the United States with the likes of University of Houston and the NCAA Basketball #VegasBubble, as well as, recently being recognized by TELUS as one of the most advanced IoT solutions in the world for their customers.

EMPOWER CLINICS

Empower’s rapid antigen and antibody tests produce results in only 15 minutes, providing airlines, cruise ships and the 182 countries currently in full or partial shutdown with the safety and security necessary to fully reopen their borders to international travel. Moreover, Empower’s KAI Medical Laboratory is a high-complexity accredited laboratory that provides reliable and accurate testing solutions to enterprise level clients, including the gold standard COVID-19 RT-PCR testing  with the capacity to process 4,000 tests per day. Empower recently announced a deal to provide a major film and television studio with 1,000 such tests.

Together, the two companies believe the Travel Bubble combination of frequent testing and a robust international tracing platform provides the end-to-end protection necessary to spark a strong global economic recovery.

Sounds too good to be true?  Both companies still have to execute but they advise that advanced discussions are already underway with major airlines, cruise ship companies and hotel operators.

Watch or listen to this powerful interview with Empower CEO, Steve McAuley and Loop CEO, Rob Anson to learn more about their potential game changing Travel Bubble solution.

Loop Insights $MTRX.ca and Empower Clinics $CBDT.ca Combine Venue Tracing With #COVID19 Testing Expertise to Create First Ever “Travel Bubble” Solution for Global Travel Industry Set to Lose $3.3 Trillion $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:21 AM on Monday, October 19th, 2020
https://miro.medium.com/max/3150/1*f9msDHyceA_TbRM30jQhsw.png
  • Partnership to provide an end-to-end COVID-19 mitigation solution complete with venue tracing, real-time automated guest exposure notifications, and frequent testing with rapid results in 15 minutes.
  • Together, Loop and Empower have created a system built on the pillars of:
  • Venue tracing
  • Frequent testing with rapid results
  • Real-time reporting to ensure the travel bubble provides end-to-end protection

VANCOUVER, British Columbia, Oct. 19, 2020 — Loop Insights Inc. (MTRX:TSXV) (RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated contact tracing to the brick and mortar space, is pleased to announce a partnership with Empower Clinics (CBDT:CSE) (EPWCF:OTC) (8EC:FRA) to provide an end-to-end COVID-19 mitigation solution complete with venue tracing, real-time automated guest exposure notifications, and frequent testing with rapid results in 15 minutes.

TRAVEL BUBBLE SOLUTION SOLVES CURRENT QUARANTINE REQUIREMENTS THAT ARE SHUTTING DOWN INTERNATIONAL TRAVEL
As a result of the COVID-19 Pandemic, mandatory 14 day quarantine periods, and the lack of any travel bubble solutions that could reliably track and mitigate the global spread of the virus by plane or cruise ship, countries have been forced to take drastic measures that are leading to significant damage of the global travel industry.

Specifically, as of today, travel restrictions by country are as follows:

  • 58 countries are completely closed
  • 124 countries are partially open with MANDATORY quarantine upon arrival

(Source – https://www.ca.kayak.com/travel-restrictions)

Together, Loop and Empower have created a system built on the pillars of:

  • Venue tracing
  • Frequent testing with rapid results
  • Real-time reporting to ensure the travel bubble provides end-to-end protection

Empower’s rapid antigen and antibody tests produce results in only 15 minutes, providing airlines, cruise ships, and the 182 countries currently in full or partial shutdown with the safety and security necessary to reopen their borders to international travel fully.

Moreover, Empower owns KAI Medical Laboratory, a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to enterprise level clients, hospitals, medical clinics, pharmacies, and employer groups.

KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. COVID-19 RT-PCR testing is the gold standard due to its high degree of accuracy and will play an important role in the Travel Bubble solution.

As the front-facing part of the Travel Bubble solution, Loop Insights is a powerful Artificial Intelligence company whose industry-leading venue tracing has gained significant traction towards reopening the tourism, hospitality, and entertainment industries in the United States with the likes of University of Houston and the NCAA Basketball #VegasBubble, as well as, recently being recognized by TELUS as one of the most advanced IoT solutions in the world for their customers.

Loop Insights CEO Rob Anson stated: “We have heard from stakeholders in the entertainment, travel, and hospitality industries that have stressed the importance of an end-to-end integrated solution capable of protecting employees and customers to facilitate a safe economic recovery. In partnership with Empower’s rapid testing technology, Loop has established a comprehensive solution capable of establishing a travel bubble and reopening a significant portion of the global economy.”

Steven McAuley, Chairman and CEO of Empower Clinics, stated: “As we expand our efforts on the Get Back To Work testing initiative, it has become apparent that businesses of all types, large or small, private or public sector require not only fast and accurate COVID-19 testing, but also a comprehensive solution for contact tracing. Establishing a partnership with Loop, working with the RT-PCR and rapid testing capabilities of Kai Medical, allows our companies together to establish a safe and viable economic recovery solution.”

AIR CANADA ADVOCATES FOR TEST-BASED APPROACH AND DROPPING 14-DAY MANDATORY QUARANTINE
The Travel Bubble solution comes at a time when both major industry participants and economic experts are calling for solutions beyond quarantining to reopen industries and stave off economic collapse.

On October 6th, Air Canada (AC:TSX) (ACDVF:OTCQX) called for increased testing in lieu of mandatory quarantine periods,

We believe that a test-based strategy may be a safe alternative to the 14-day quarantine.”

On October 15, 2020 a panel of Canadian economists proclaimed the “economy must remain open despite second wave” or suffer the very likely outcome of bankruptcies and business closures “with hospitality, travel and tourism set for the harshest impact.”

By providing testing, tracking, and real-time reporting, Loop and Empower have created a safe and secure Travel Bubble solution to allow enterprise level businesses to return to full operations, particularly those in the hospitality, travel, and live entertainment industries.

$3.3 TRILLION IN LOSSES FOR GLOBAL TOURISM INDUSTRY

Without a solution to replace the drastic travel measures currently in place around the world, the United Nations Conference on Trade and Development (UNCTAD) reported that COVID-19 may cost the world tourism sector losses of US$ 3.3 trillion.

In Canada alone, according to Statista, the Canadian tourism industry contributed close to $40 billion to the economy in 2019. This year, the COVID-19 pandemic has had devastating consequences for the industry.

Loop and Empower believe the Travel Bubble combination of frequent testing and a robust international tracing platform provides the end-to-end protection necessary to spark a strong global economic recovery. 

This press release is available on the Loop Insights Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/LoopInsights

About Empower:

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative. Empower recently acquired Kai Medical Laboratory, LLC as a wholly-owned subsidiary with large-scale testing capability. 

About Loop Insights:

Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network and sold through the TELUS IoT Marketplace.

For more information, please contact: 
Loop Insights Inc.LOOP Websitewww.loopinsights.ai
Rob Anson, CEOFacebook: @LoopInsights 
T: +1 877-754-5336 Ext. 4Twitter: @LoopInsights 
E[email protected]LinkedIn: @LoopInsights 

Forward-Looking Statements/Information: 

This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

8 Small Cap #Cannabis Companies That Will Lead The Next Growth Cycle For The $97 Billion Market By 2026 $AVCN.ca $CBDT.ca $HBOR.ca $HOLL.ca $INNO.ca $SPDR.ca $TBI.ca $TCAN.ca

Posted by AGORACOM-JC at 3:39 PM on Thursday, October 8th, 2020

Despite the collapse of marijuana and cannabis related stocks in the last 18 months, there is no denying that Cannabis related products are going to go through a paradigm shifting, parabolic growth stage around the world over this decade for the following reasons:

  1. Cannabis legalization is gaining momentum around the world.
  2. Momentum is primarily driven by the realization that cannabis may have a range of medicinal, therapeutic and wellness applications.
  3. It is the most widely cultivated, consumed and trafficked drug worldwide (United Nations Office on Drugs and Crime).

So what is this going to translate into?

The global cannabis market size was valued at $US 10.6 Billion in 2018 and is projected to reach $97.5 Billion by the end of 2026, a CAGR of 32.92% (Fortune Business Insights)

WHY WILL THIS TIME BE DIFFERENT?

Big promises, big IR budgets, big hype …. Big Letdown.

That pretty much sums up the last cycle of Cannabis related companies that focused on speed, stories and stock prices rather than the one simple but important thing they should have been doing – building a real business.

Investors will remember that the same thing happened during the dot-com era.  As with the cannabis collapse over the last 18 months, what followed back in 2000 was a long period of mourning in which many investors had sworn off tech stocks, just as they have with cannabis stocks today.

But it wasn’t long until tech investors dusted themselves off and realized tech was here to stay – but this time they were only going to focus on real companies with real businesses.  What we got was Amazon, Google, Linkedin, Facebook and then the rest was history.

The same thing is about to happen to the Cannabis sector

Meet the 8 new horsemen of the next leadership group that are firing on all cylinders (in alphabetical order).

Avicanna (AVCN :TSX) (AVCN : OTCQX) ( 0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.

When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:

1.  The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year.  These are the only known CBD cosmetics backed by clinical trials.

2.  Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia.

3.  Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.

AND… if that is not enough …

4.  Avicanna’s Colombian cultivation division hosts 500,000 Sq ft of low cost and USDA certified organic Cannabis Cultivation. The company recently Made History As The First Ever Export Of Feminized Hemp Seeds From Colombia To The United States. 7,000,000 Seeds For $380,000, with an additional 75,000,000 Seeds Available For Export In Several Pending Transactions.

For more information about the company, please check out the Avicanna HUB on AGORACOM.

Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for … but then these numbers recently came in for the first two quarters to further cement Empower as a leader:

PatientVisits

  • Q1 + 377% To 5,717
  • Q2 + 56% To 6,696

Revenues $USD

  • Q1 + 416% To $790,000 (NO COVID)
  • Q2 + 56% To $923.000

TOTAL Q1 AND Q2

  • REVENUE                 $1.7M vs $745K         = + 130%
  • PATIENTS                 12,400 vs 5,500           = + 125%
  • NET LOSS                 $920K vs 1.85M         = – 50% 

Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019. 

BONUS – The Company’s physician staffed clinics have are also generating significant revenue and growth from the COVID-19 pandemic as follows: 

  • Increased CBD treatments from patients suffering increased anxiety;
  • Testing for individuals and families
  • Testing for local businesses and employees 
  • Testing for enterprise level organizations across the country 
  • Acquisition of an 8,000 sq ft lab in Dallas that can process 4,000 COVID-19 tests per day
    • At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY

Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never.  Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.

For more information about the company, please check out the Empower HUB on AGORACOM.

Harborside (HBOR: CSE), (HSDEF: OTCQX) has generated over $400,000,000 (NOT a typo) since its inception in 2006.  We thought that would get your attention.

What Do They Do?

HBOR is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments:

1. Retail Dispensaries

2. Wholesale

3. Cultivation and Processing

HIGHLIGHTS

  • Founded in 2006. One of the oldest and most respected cannabis retailers in California
  • Awarded one of the first six medical cannabis licenses in the USA
  • Operations have generated over $400M in cumulative sales since inception
  • Retail operations command 3% of California’s entire retail market
  • 2020 Financials (Q1 +  Q2)

○       Revenues         $30,800,000

○       Gross Profit     $14,000,000

○       EBITDA            $1,100,000

  • Expected to generate approximately $62M – $65M in sales in 2020
  • Operate California’s only drive-through dispensary 
  • Over 1,300 customers per day in Q2
  • Oakland dispensary is one of the largest retail cannabis locations in the world
  • 2020E Guidance
    • ~$44M Retail Revenue
    •   ~$21M Wholesale Revenue
    • ~$62M – ~65M Total Revenue

For more information about the company, please check out the Harborside Inc  hub on AGORACOM.

Hollister Biosciences Inc. (HOLL:CSE) (HSTRF:OTC) (HOB: FRANKFURT) is a multi-state cannabis company with products in 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, translating into the following great success:

  • Revenues $USD
    • Q1 +317%  YoY to $862,000
    • Q2 +3685% YoY to  $8,500,000
  • TOTAL Q1 AND Q2
    • REVENUE                 $9.4M vs $428K     = + 2096%
    • GROSS PROFIT        $1.2M vs ($133K)   = + 1002%

In addition to organic sales, Hollister has several high-level partnerships that demonstrate how trusted the Company is within the industry, including:

Hollister is also the creator of California’s most hash-infused pre-roll HashBone

For more information about the company, please check out the Hollister Biosciences Inc. hub on AGORACOM.

Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.

3 Fully Operating Divisions For Investor Diversification

Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

  1.  PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.
  2. CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
  3. OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.

Global Manufacturing / Distribution Agreements

  • Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
  • Swiss CBD provider Cloud 9 Switzerland LLC (Distribution – Italy and Switzerland)
  • Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)

Superior Management Team

In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself.  The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:

  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.

Together they have built one of the most formidable teams in the small cap cannabis world

For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.

Spyder Cannabis Inc. (SPDR :TSXV) is a Cannabis, Vape and CBD retailer with three retail business units.

  1. SALE OF CANNABIS PRODUCTS – The Company has TWO cannabis dispensaries currently in operation. The first being a location in Calgary, Alberta and the second in Niagara Falls. Both dispensaries are located in busy commercial hubs. The management team is currently evaluating several additional locations in both Alberta and Ontario where it intends to expand the Spyder Cannabis brand’s footprint.
  2. SALE OF HEMP CBD (US) Company is also pursuing the sale of Hemp based CBD products from locations in the USA.
  3. SMOKING CESSATION PRODUCTS IN ONTARIO The company sells electronic cigarettes, E-juice and accessories for the “vape” business from five Canadian retail locations; Woodbridge, Scarborough, Pickering, Niagara Falls and Burlington, Ontario. Spyder has established itself as a savvy retailer.

For more information about the company, please check out the Spyder Cannabis  hub on AGORACOM.

Thoughtful Brands, Inc. (TBI: CSE)( 1WZ1: FWB)( PEMTF: OTCQB) is a global natural health products and eCommerce technology company that is operating at full throttle. 

  • Acquired eCommerce retailers with combined total sales of approximately $29,000,000 with an EBITDA of approximately 12.5%.
  • Current customer base of over 200,000 customers with additional leads of over 600,000 potential new customers
  • Enhanced eCommernce solution through Unified Funding’s software which facilitated over $350 million in consumer transactions (CAD $93.8 million) in 2019 from more than one million paying customers.
  •  Low-cost production will be vertically integrated into retail brands to achieve up to 20x margin increase.

We’ll let these revenue numbers speak for themselves.

  • August 2020 CAD $3,809,000
  • July 2020 CAD $2,340,000
  • June 2020 CAD $2,712,000

The above represents an increase of 19%, over the same period in 2019.

QUARTERLY REVENUE $CAD

  • Q1 $7,600,000 Growth
  • Q2  $12,800,000 Growth 

TOTAL Q1 AND Q2

  • REVENUE  $20,400,000
  •  GROSS PROFIT  $2,154,357

The company has its sights set on European expansion through a joint venture with Franchise Cannabis Corp. The company will now sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the UK, utilizing its eCommerce platform.

The company also completed acquisition of Verrian, which owns and operates a 110,000-square foot pharmaceutical manufacturing facility in Radebuel, Germany. This acquisition will assist the company in tapping into the burgeoning market for psychedelics as Verrian specializes in developing psychedelic derived medicines for treatments for addictions, including opioids and alcohol.

For more information about the company, please check out the Thoughtful Brands hub on AGORACOM. 

TransCanna (TCAN:CSE) (TH8:FSE) owns a 196,000 square foot cannabis Facility, the largest known fully licensed cannabis facility in California.

  • CAD $24.9M  Revenue Run Rate from 10,000 sq.ft  test facility
  • CAD $90M Annual Revenue expected from first full year of production at Fully Licensed Daly Street Facility.
  • Acquired two California companies,
  • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented 
  • Direct to dispensary model, cutting out the middleman

 REVENUES  $CAD

  • Q1  $906,000
  • Q2  $4,300,000

 TOTAL Q1 AND Q2

  • REVENUE     $5,206,000    
  • GROSS MARGIN $1,920,000

For more information about the company, please check out the TransCanna hub on AGORACOM.

Thanks for reading and discovering these great small cap cannabis companies.  Please be sure to visit the AGORACOM Small Cap Cannabis Gateway often to stay up to date with new companies at:

https://agoracom.com/portal/Small-Cap-Marijuana-Cannabis-Stocks

VIDEO – Empower Clinics $CBDT.ca Acquires Testing Lab And Lands First COVID-19 Testing Contract For Major Film & TV Studio $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 6:42 PM on Wednesday, October 7th, 2020

Sometimes, you just have to let the numbers speak for themselves.  With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for … but then these numbers came in for the first two quarters:

Revenues $USD 1.7M vs $745,000 = 130% Gain

Patient Visits 12,400 vs 5,500 = 125% Gain

CBDT has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.

But he is far from done.

In the last 36 hours, Empower announced:

1.  The acquisition of an 8,000 sq ft lab in Dallas (they do everything big over there) that can process 4,000 COVID-19 tests per day.  At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY.  We will let you do the math with the combination of higher prices + more tests per day.

2.  An agreement to run 1,000 COVID-19 RT-PCR Tests for a major film & TV studio, which could lead to much more business if all goes well with this first batch. To this end, the lab has already processed tests for six different film and television productions since September 1st (prior to the acquisition) and continues to build both confidence and credibility within the industry.

It doesn’t take much to see that the lab has the potential to take Empower to a whole new level.  Specifically, if you’re an investor in Well Health (WELL:TSX) and/or CloudMD (DOC:TSXV) you have to start taking a serious look at Empower as the next great potential health and wellness company.  It’s already proven solid revenues and growth from its clinics, is expanding its telemedicine practice very nicely and now has the power to quickly generate significant enterprise level revenues from its newly acquired medical diagnostics laboratory … which is already bearing fruit just 24 hours after the acquisition.

Can McAuley pull it off?  First consider what he has already accomplished after inheriting a catastrophe of a company in early 2019.  Secondly, McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth through Q2 2020 … with some jet fuel now added here in Q4.

And if you MISSED Well Health and CloudMD, you really need to take a close look at Empower as the next great small cap health & wellness company.

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Empower Clinics $CBDT.ca Acquires Medical Laboratory Capable of Processing 4,000 #COVID-19 RT-PCR Tests Per Day $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:02 AM on Tuesday, October 6th, 2020

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX, will advance Empower COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses, colleges and universities

  • Pursuant to the terms of a membership interest purchase agreement dated October 5, 2020, has completed the acquisition of Kai Medical Laboratory, LLC (“KAI“) from KTM5 Holdings, LLC, NULV11, LLC and Consistent Investment Group, LLC (together, the “Vendors“), through its wholly-owned subsidiary, Empower Healthcare Assets Inc. (“Empower Health“), for consideration having an aggregate value of US$1,971,857 (CAD$2,613,478), effective as of October 5, 2020 (the “Transaction“).

VANCOUVER BC / October 6, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (Frankfurt:8EC) (OTCQB:EPWCF) (“Empower” or the “Company“) is pleased to announce that, pursuant to the terms of a membership interest purchase agreement dated October 5, 2020, has completed the acquisition of Kai Medical Laboratory, LLC (“KAI“) from KTM5 Holdings, LLC, NULV11, LLC and Consistent Investment Group, LLC (together, the “Vendors“), through its wholly-owned subsidiary, Empower Healthcare Assets Inc. (“Empower Health“), for consideration having an aggregate value of US$1,971,857 (CAD$2,613,478), effective as of October 5, 2020 (the “Transaction“).

COVID-19 RT-PCR TESTING IS THE GOLD STANDARD THAT ALLOWS EMPOWER TO ROLL OUT NATIONAL PHASE 4 TESTING PROGRAMS

KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including movie and television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.

“Adding Kai Medical Laboratory to the Empower Clinics family enables us to dramatically expand COVID-19 testing capability, for our get back to work & get back to school initiatives as part of our national rollout plans” said Steven McAuley, Empower’s Chairman & CEO. “Kai Medical has a newly built high-complexity lab offering a wide array of testing services, that we will leverage to serve the massive demand for national COVID testing in the U.S. Additionally, as flu season arrives and a potential second-wave of COVID takes hold, the technical infrastructure of Kai Medical allows Empower to capture testing demand and bring new technical testing products to market.”

COVID-19 TESTING PROGRAMS FOR EMPLOYERS AND DIRECT TO CONSUMER ALREADY UNDERWAY AT KAI LABORATORY

To further assist with COVID-19 testing, Kai Medical Laboratory has also developed two key programs in Texas and Arizona. The first program is a direct-to-consumer program that leverages the ability of various healthcare providers to order and administer both the RT-PCR test and the Antibody test. This increases the ability of the general population to be tested, in certain circumstances. The second is an Employer COVID-19 Compliance Program (ECCP) for business owners and employer groups to enable them to test and monitor their employees.

Texas program https://www.testtexasnow.com

Arizona program https://www.covidtest2u.com

Finally, beyond its COVID-19 capabilities, Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals and pharmacists.

KAI MEDICAL LABORATORY TEAM LEAD BY YOSHI TYLER

The driving force behind Kai Medical Laboratory’s remarkable growth and success is Yoshi Tyler. Yoshi has a passion for being an entrepreneur, and over time, she found her true calling in healthcare. Driven by this interest, she pursued her career in the healthcare industry for more than two decades. She held leadership positions at a Fortune 500 pharmaceutical company for over thirteen years. These leadership experiences provided her with in-depth knowledge and industry insights that helped her to lead Kai Medical Laboratory towards growth.

The Kai Medical Laboratory team includes key roles including Principal Scientist, Director of Operations, Molecular Scientist, Quality Assurance, Lab Director and other critical roles.

“Kai Medical Laboratory is inspired by science and built on integrity and joining Empower allows our highly skilled personnel and state-of-the-art instrumentation to expand from a local community level to a national level” says Yoshi Tyler, Founder of Kai Medical. “Our mission is to change healthcare through science & innovative quality care, and with Empower providing an expansion of resources, Kai Medical Laboratory will be in a position to help the national need for expanded COVID-19 testing as the second wave commences.”

ADDITIONAL TERMS OF THE ACQUISITION

In connection with the closing of the Transaction (the “Closing“), Empower; (i) assumes certain short term and long term liabilities comprised of the SBA Loan of (US$1,139,577), the EIDL Loan of (US$150,000), the PPP Loan of (US$86,379), revolving debt of (US$89,478), (ii), accounts payable of (US$192,460), (iii) other short term and long term liabilities of (US$313,963), in total equal to the amount of US$1,971,857 (CAD$2,613,478), (the “Assumed Indebtedness“); the issuance of options to purchase common shares of Buyer Parent at an exercise price of CDN$0.05 per share, subject to the terms and conditions of each of the Option Agreements, in an amount equal to 400,000 share options to Yoshi Tyler, as the principal of KTM5, and 100,000 share options to Michael Haines, as the principal of NULV11 (the “Options“); and the issuance of a warrant certificate to Continuous Investment Group, LLC to purchase 500,000 common shares of Buyer Parent at a purchase price of CDN$0.05 per share, subject to the terms and conditions of the Warrant Certificate (the “Warrants“).

Market Leading Technology Kai Medical Laboratory utilizes state-of-the-art instrumentation, preeminent testing methodologies, and laboratory services enabling high-complexity accredited laboratory testing solutions, providing some of the following key instrument testing capabilities:

  • Thermo Fisher – QuantStudio 12K Flex
    • COVID-19 testing
    • Cannabis Testing
    • Clinical Genomics
  • Roche Cobas 6000
    • COVID-19 Antibody testing
    • Clinical Chemistry/Endocrinology
  • AB SCIEX 6500+ – Liquid Chromatography Mass Spectrometry
    • Clinical Chemistry/Endocrinology
    • Agriculture/Cannabis testing
  • AB SCIEX 4500 – Liquid Chromatography Mass Spectrometry
    • Urine Toxicology
    • Cannabis testing
  • SYSMEX XN-550
    • Hematology

(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.

(COLA) is the premier clinical laboratory accreditation, education and consultation organization. An independent accreditor whose practical, educational standards have a positive and immediate impact on patient care. http://www.cola.org

ABOUT EMPOWER

Empower is an integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.

ABOUT Kai Medical Laboratory

Our mission is to change healthcare through science & innovative quality care by providing value added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas).

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: EMPOWER CLINICS INC.

VIDEO – Empower Clinics $CBDT.ca Grows Revenues 130%, Patient Visits 125% And Becomes Cash Flow Positive $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 4:03 PM on Wednesday, September 16th, 2020

Sometimes, you just have to let the numbers speak for themselves.  With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for … but then these numbers came in for the first two quarters:

Revenues $USD 1.7M vs $745,000 = 130% Gain

Patient Visits 12,400 vs 5,500 = 125% Gain

CBDT has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.

But he is far from done.

CBDT also just announced the potential acquisition of an 8,000 sq ft lab in Dallas (they do everything big over there) that can process 2,000 COVID-19 tests per 8 hour shift.  At an average price of ~ $USD 90 per test, the clinic could represent $USD 180,000 in revenue PER SHIFT.  However, until this acquisition closes, we’re not going to focus on it too much – but that could happen as early as next week.  

Moreover, CBDT has to actually fill that capacity, which McAuley says he is working on right now with some enterprise sized discussions taking place as we write. Can he pull it off?  First consider what he has already accomplished after inheriting a catastrophe of a company.  Secondly, McAuley, is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth … and gives us optimism about this acquisition.

Watch this amazing interview.

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Empower Clinics $CBDT.ca Expands COVID-19 Testing Programs by Commencing RT-PCR Testing $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:56 AM on Thursday, September 10th, 2020
  • Commenced COVID-19 reverse transcription polymerase chain reaction (RT-PCR), testing through its Sun Valley Health operations in Arizona, using RT-PCR test kits and laboratory test processing by Kai Medical Laboratory in Dallas, TX., the recently announced proposed acquisition target by Empower
  • programs are part of a “Back to Work” and “Back to School” initiative supported by a variety of outbound marketing campaigns including new Facebook ads, text message & email campaigns and outbound call-center campaigns targeting businesses, universities & colleges, sports teams or organizations where effective social distancing could be difficult.

VANCOUVER BC / September 10, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) today announces it has commenced COVID-19 reverse transcription polymerase chain reaction (RT-PCR), testing through its Sun Valley Health operations in Arizona, using RT-PCR test kits and laboratory test processing by Kai Medical Laboratory in Dallas, TX., the recently announced proposed acquisition target by Empower.

The programs are part of a “Back to Work” and “Back to School” initiative supported by a variety of outbound marketing campaigns including new Facebook ads, text message & email campaigns and outbound call-center campaigns targeting businesses, universities & colleges, sports teams or organizations where effective social distancing could be difficult.

RT-PCR Testing can be booked via: https://www.sunvalleyhealth.com/covid-19-test-book-now/

Currently Kai Medical Laboratory has the capacity to complete in excess of 2,000 RT-PCR tests in one eight-hour shift by utilizing its Thermo Fisher QuantStudio 12k Flex testing machine.

“Launching our RT-PCR testing programs utilizing the capability of Kai Medical Labs gives us the ability to access massive testing volume not only in Arizona, but nationwide in the U.S.” said Steven McAuley, Empower’s Chairman & CEO. “Our team at Sun Valley Health has created numerous strategic marketing campaigns to drive awareness and testing volume, leveraging our supply chain improvements with increased profit margins.”

Many schools and universities are now requiring students and teachers to provide RT-PCR testing results prior to returning to campus. Our nasal or throat swab RT-PCR testing program allow students and teachers to quickly be tested and receive results from a Clinical Laboratory Improvement Amendments (CLIA), accredited laboratory in only 24 – 48 hours.

Businesses need a stable workforce, and must be quick to isolate employees with any symptoms. Our RT-PCR testing allows employees to be tested quickly and receive results within 24 – 48 hours, giving the employee and the employer the opportunity to activate non-contagious employees and safely return to work!

Travelers are also discovering demands to get a RT-PCR test and provide the result upon check-in at the airport. The reports are required to be no more than 3 days old. Our testing program provides accurate results within 24-48 hours, giving the patient a document that can make the difference in being able to travel.

https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-testing.html
https://www.wsj.com/articles/universities-plan-robust-covid-19-testing-for-returning-students-11594812937

An RT-PCR assay is a viral molecular test to detect active infection directly in a patient’s RNA genetic sequence. An RT-PCR swab test is considered the gold-standard for testing & diagnosing active viral infections and should be used for anyone who has symptoms or known exposure to COVID-19. These tests are renowned for high sensitivity and high specificity.

(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.

USA COVID-19 Data as at September 9, 2020
TOTAL CASES: 6,310,663
TOTAL DEATHS: 189,147
CASES IN LAST 7 DAYS: 262,971

ARIZONA as at September 9, 2020
CONFIRMED CASES: 204,239
PROBABLE CASES: 1,806
TOTAL CASES: 206,045
CASES IN LAST 7 DAYS: 3,703
CASES/100K: 2,873
DEATHS/100K: 72

TEXAS as at September 9, 2020
TOTAL CASES: 641,791
CASES IN LAST 7 DAYS: 24,458
CASES/100K: 2,236
DEATHS/100K: 47

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.

ABOUT Kai Medical Laboratory

Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals, and pharmacists. https://www.kaimedicallaboratory.com

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the proposed acquisition of Sun Valley; the proposed transaction terms; the expected number of clinics and patients following the closing; the future potential success of Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Empower Clinics $CBDT.ca Announces Acquisition of Medical Diagnostics Laboratory $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:06 AM on Tuesday, September 1st, 2020

Empower intends to acquire Kai Medical Laboratory, a state-of-the-art diagnostics laboratory located in the medical district of Dallas, TX to advance COVID-19 national testing programs

  • Entered into a non-binding term sheet to acquire the business of Kai Medical Laboratory, LLC, by way of a share or asset acquisition, subject to due diligence and customary closing conditions
  • Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups
  • Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology

VANCOUVER, BC / September 1, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (Frankfurt:8EC) (OTCQB:EPWCF) (“Empower” or the “Company“) today announces it has entered into a non-binding term sheet to acquire the business of Kai Medical Laboratory, LLC (“Kai Medical Laboratory“), by way of a share or asset acquisition, subject to due diligence and customary closing conditions.

Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals, and pharmacists. https://www.kaimedicallaboratory.com

Kai Medical Laboratory has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

To further assist with COVID-19 testing, Kai Medical Laboratory has also developed two key programs in Texas and Arizona. The first program is a direct-to-consumer program that leverages the ability of various healthcare providers to order and administer both the RT-PCR test and the Antibody test. This increases the ability of the general population to be tested, in certain circumstances. The second is an Employer COVID-19 Compliance Program (ECCP) for business owners and employer groups to enable them to test and monitor their employees.

Texas program https://www.testtexasnow.com

Arizona program https://www.covidtest2u.com

Currently the lab has the capacity to complete in excess of 2,000 RT-PCR tests in one eight-hour shift by utilizing its Thermo Fisher QuantStudio 12k Flex testing machine. The lab also utilizes a Roche Cobas 6000 for COVID-19 Antibody testing, ensuring that Kai Medical Laboratory has the capability and capacity to serve a broad range of clients and test methods.

“Adding Kai Medical Laboratory to the Empower Clinics family enables us to dramatically expand COVID-19 testing capability and deliver phase four of our national rollout plan” said Steven McAuley, Empower’s Chairman & CEO. “Kai Medical has a newly built high-complexity lab offering a wide array of testing services, that together we will leverage to serve the massive demand for national COVID testing in the U.S. Further, as flu season arrives and a potential second-wave of COVID takes hold, the technical infrastructure of Kai Medical allows Empower to capture testing demand and the additional growth revenues associated with it.”

The driving force behind Kai Medical Laboratory’s remarkable growth and success is Yoshi Tyler. Yoshi has a passion for being an entrepreneur, and overtime, she found her true calling in healthcare. Driven by this interest, she pursued her career in the healthcare industry for more than two decades. She helmed leadership positions at a Fortune 500 pharmaceutical company for over thirteen years. These leadership experiences provided her with in-depth knowledge and industry insights that helped her to lead Kai Medical Laboratory towards growth.

The Kai Medical Laboratory team includes key roles including Principal Scientist, Director of Operations, Molecular Scientist, Quality Assurance, Lab Director and other critical roles.

“Kai Medical Laboratory is inspired by science and built on integrity. Our mission is to change healthcare through science & innovative quality care by providing value-added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in healthcare,” says Yoshi Tyler, the owner, and CEO of the company.

The proposed acquisition includes an 8,000 sq. ft. medical laboratory including covered drive up testing center, with premium testing and laboratory equipment, cash and current assets with a value in excess of $1,750,000.00 USD and a corporate office, both located in the heart of the medical district in Dallas, TX. Under the proposed terms Empower will assume a $1,200,000.00 USD Small Business Administration (SBA) equipment loan, a $150,000.00 SBA Economic Injury Disaster Loan and short-term liabilities of up to $250,000.00 at closing. In addition, Empower will issue 1,000,000 Company stock options to the Vendors, subject to the terms and conditions as set out in the Company Stock Option Plan.

Market Leading Technology Kai Medical Laboratory utilizes state-of-the-art instrumentation, preeminent testing methodologies, and laboratory services enabling high-complexity accredited laboratory testing solutions, providing some of the following key instrument testing capabilities:

  • Thermo Fisher – QuantStudio 12K Flex
    • COVID-19 testing
    • Cannabis Testing
    • Clinical Genomics
  • Roche Cobas 6000
    • COVID-19 Antibody testing
    • Clinical Chemistry/Endocrinology
  • AB SCIEX 6500+ – Liquid Chromatography Mass Spectrometry
    • Clinical Chemistry/Endocrinology
    • Agriculture/Cannabis testing
  • AB SCIEX 4500 – Liquid Chromatography Mass Spectrometry
    • Urine Toxicology
    • Cannabis testing
  • SYSMEX XN-550
    • Hematology

USA COVID-19 Data as at August 31, 2020

TOTAL CASES: 5,972,356

TOTAL DEATHS: 182,622

CASES IN LAST 7 DAYS: 289,865

ARIZONA as at August 31, 2020

CONFIRMED CASES: 199,984

PROBABLE CASES: 1,713

TOTAL CASES: 201,661

CASES IN LAST 7 DAYS: 3,558

CASES/100K: 1,769

DEATHS/100K: 70

TEXAS as at August 31, 2020

TOTAL CASES: 610,354

CASES IN LAST 7 DAYS: 32,817

CASES/100K: 2,126

DEATHS/100K: 46

(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.

(COLA) is the premier clinical laboratory accreditation, education and consultation organization. An independent accreditor whose practical, educational standards have a positive and immediate impact on patient care. http://www.cola.org

The transaction is expected to be structured on a tax efficient basis, and otherwise in accordance with the requirements of requisite securities laws and the policies of the CSE. Empower has agreed to enter into employment agreements with Yoshi Tyler and Michael Haines, each having an initial term of two years.

Completion of the transaction will be subject to various conditions, including entry into a definitive agreement, completion of due diligence, and receipt of all required shareholder, manager, third party and regulatory approvals, including approval of the CSE. Closing of the transaction is expected to occur prior to October 15, 2020.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.

ABOUT KAI MEDICAL LABORATORY

Our mission is to change healthcare through science & innovative quality care by providing value added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas).

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein

Director
[email protected]
720-352-1398

Investors: Steven McAuley

CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the proposed acquisition of Sun Valley; the proposed transaction terms; the expected number of clinics and patients following the closing; the future potential success of Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.